FIRST isolated in 1949 from the gram-positive bacillus Streptomyces fradiae, neomycin belongs to the aminoglycoside family of antibiotics. It consists of a mixture of two isomers, neomycin B and neomycin C, along with small amounts of a degradation product, neamine or neomycin A.1 It exerts its antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis.2 Neomycin is effective against most gram-negative organisms except Pseudomonas aeruginosa and anaerobic bacteria. Its activity against gram-positive microorganisms is more or less limited to staphylococci, but bacterial resistance supervenes after prolonged use.
Percutaneous absorption after topical application is minimal, and absorption through intact gastrointestinal mucosa is poor, ranging between 1% and 3%. Parenteral administration is associated with severe oto- and nephro-toxicity, at times irreversible. Neomycin is therefore used (1) in topical formulations for the prevention and treatment of superficial skin, ear, and eye infections; (2) in solutions for urinary instillations to prevent bacteriuria from indwelling catheters; and (3) in peritoneal irrigation solutions used to treat contaminations in abdominal surgery. Dentists may use a neomycin-containing paste in root canal treatment. Given orally in doses of 200 to 1,000 mg two to four times per day, neomycin is used to sterilize the gut before digestive tract surgery and is also used in the treatment of hepatic coma (to reduce the number of ammoniagenic intestinal bacteria). In addition, trace amounts of neomycin are present in numerous vaccines as a result of its use to prevent bacterial contamination during the vaccines' manufacture (Table 1).
Contact Hypersensitivity to Neomycin
Allergic contact dermatitis from neomycin was first described in 1952.3 Prystowsky and colleagues determined the frequency of neomycin sensitization in the general population to be 1.1%.4 Reported sensitization rates in selected patient populations referred for patch testing vary from one country to another. In 10 European centers, the rates varied from 1.1 to 3.8% and averaged 1.9%.5 A multifactorial analysis of German data found a global prevalence of neomycin sensitization of 2.5% in patchtested patients.6 Published results from the North American Contact Dermatitis Group reveal sensitization rates that are much higher and that have remained remarkably stable through the years, from 11.6% in the 1994-1996 study period to 10% in the 2005-2006 period.7 According to this group's database, neomycin is now the fifth most common allergen in North America and was the third most common in the previous study period. This higher rate of sensitization stems from the availability of this antibiotic in numerous over-the-counter preparations, especially “triple antibiotic” creams and ointments. Subgroups at higher risk include patients with stasis dermatitis and leg ulcers, anogenital dermatitis, and otitis externa.8
Because antibiotic preparations are applied to already damaged skin, allergic contact dermatitis from neomycin is not always easily recognized. It often presents as the persistence or worsening of a preexisting dermatitis.9 An intensification of itch and the progression of lesions beyond the initial site of involvement may offer clues to the correct diagnosis. Occupational dermatitis involving the hands (and sometimes the face) can occur in nurses, physicians, pharmacists, dentists, and veterinarians.10
Patch Tests with Neomycin
The usual concentration of neomycin in topical formulations is 0.5%. However, patch testing on normal skin with the commercial preparation almost always yields negative results owing to poor penetration through an intact epidermal barrier. To overcome this difficulty, patch testing with neomycin is done with a concentration of 20% in petrolatum (230 μg/cm2 in the Thin-Layer Rapid Use Epicutaneous [T.R.U.E.] Test [Mekos Laboratories A/S, Hillerød, Denmark]). Even at that concentration, false-negative reactions may occur in 10% of cases.11 When contact allergy is strongly suspected in the face of a negative patch-test result, repeated open application tests with the commercial preparation4 or patch tests with a 20% aqueous solution of neomycin12 may eliminate the need for intradermal tests. When intradermal tests are required, a 1% sterile solution of neomycin is used.11
Patch-test reactions to neomycin are notoriously slow to appear, peaking at 96 hours (day 4) or even at 168 hours (day 7).12 Readings must therefore be performed after 48 hours if a certain number of cases are not to be missed. Similar to what occurs with gold, positive reactions may persist for days to weeks.
Neomycin is composed of four rings joined by glycosidic bonds (Fig 1). One of the rings, the amino hexose 2-deoxystreptamine, is common to all aminoglycosides except streptomycin. In streptomycin, the hexose is streptidine, and the entire structure of the molecule differs from that of other antibiotics of the same group. Framycetin is 99% neomycin B whereas paromomycin and butirosin share close structural similarities with neomycin. Antibiotics of the kanamycin family include tobramycin and amikacin; these antibiotics share with neomycin the neosamine moiety, with slight modifications on the 2-deoxystreptamine ring. Antibiotics of the gentamicin family, including netilmicin and sisomicin, have only 2-deoxystreptamine in common with neomycin.1,13
Considering the above, it is not surprising that the percentage of cross-reactions with neomycin is about 90% for paromomycin and butirosin, 70% for framycetin, 60% for tobramycin and kanamycin, 50% for gentamicin, and only 4% for streptomycin.1,2,13-18
Because neomycin and bacitracin (2003 Allergen of the Year) are often present in the same topical preparations, it is not uncommon to observe sensitization to both antibiotics.19 Bacitracin is extracted from a strain of Bacillus subtilis, and its chemical structure bears no resemblance to that of neomycin. Thus, the frequent reactions seen with both molecules are not cross-reactions but concomitant sensitizations.
Triple antibiotic creams or ointments contain polymyxin B in addition to neomycin and bacitracin. Grandinetti and Fowler reported on the simultaneous sensitization to all three antibiotics.20 Because polymyxin B is not routinely used in standard series, the rate of sensitization to this antibiotic is unknown. Polymyxins are derived from bacteria of the genus Bacillus (Bacillus polymyxa). Because of this common source, Van Ketel believed that both antibiotics would cross-react.21 Here again, however, the chemical structure of each compound is very different, and true crossreaction appears unlikely.
Neomycin and Systemic Reactions
In an individual previously sensitized by topical exposure, the small amount of neomycin absorbed from the gastrointestinal tract may be enough to trigger widespread dermatitis or a flare-up at the site of prior contact dermatitis.22-24 Morton and colleagues described a case of acute, widespread, and weeping dermatitis in a neomycinsensitive patient from the subconjunctival injection of framycetin after cataract surgery. The patient later developed a local delayed reaction and a mild flare-up following intradermal testing with a 1% aqueous solution of framycetin.25 A flare-up of positive patch-test reactions may be seen after oral administration of neomycin,8 and patch testing has induced flare-up of previous sites of allergic contact dermatitis from neomycin.26
Systemic administration of a related aminoglycoside such as streptomycin, kanamycin, or gentamicin may be responsible for systemic contact dermatitis in patients who have been sensitized to neomycin by topical exposure. Guin and Phillips reported a case of erythroderma from systemically administered gentamicin in a neomycinallergic patient.27 To prevent infection following joint replacement, gentamicin is added to acrylate-based joint cement. Release of the antibiotic is maximal after 24 hours but continues for 6 months. One case report described the occurrence of self-limited but widespread dermatitis 3 days after knee replacement in a gentamicin-sensitive patient.28 Similar events are likely to occur through cross-reaction in patients with neomycin allergy.
Vaccination with neomycin-containing preparations poses a theoretical risk of systemic reaction. One case report described the occurrence of a type I hypersensitivity reaction from the measles, mumps, and rubella vaccine in a 7-year-old boy not known to be allergic to egg protein.29 The authors suspected neomycin as the culprit but did not perform prick or intradermal testing with the antibiotic; therefore, the true cause of their patient's reaction remains unknown. A history of anaphylaxis from neomycin would obviously preclude the administration of any vaccine that contains this antibiotic. However, Rietschel rightly pointed out that allergy to neomycin is usually of the delayed type and that the threshold for elicitation of sensitivity is 100 to 1,000 mg.30 Given that vaccines contain 25 μg of neomycin, reactions to their administration are bound to cause minimal or no local transient reactions. The Committee on Infectious Diseases of the American Academy of Pediatrics no longer considers contact hypersensitivity to neomycin a contraindication to vaccination.29
In countries such as Germany, where neomycin is available as a prescription drug, the rate of sensitization is around 1% of patients referred for patch testing. By contrast, in North America, where neomycin-containing preparations are available over the counter, the North American
Contact Dermatitis Group's results show a relatively constant rate of sensitization that varied between 10% and 13% from 1994 to 2006.7 Neomycin is not a new allergen, but it is an allergen that does not want to die. For its illustrious and long career, it is awarded the title of Allergen of the Year.
No benefits in any form have been received from any commercial party related directly or indirectly to the subject of this article.
1. Macdonald RH, Beck M. Neomycin: a review with particular reference to dermatologic usage. Clin Exp Dermatol 1983;8:249-58.
2. Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: epidemiology, responsible allergens and management. J Am Acad Dermatol 2008;58:1-21.
3. Baer RI, Ludwig JS. Allergic eczematous sensitization to neomycin. Ann Allergy 1952;10:136-7.
4. Prystowsky SD, Nonomura JH, Smith RW, Allen AM. Allergic hypersensitivity to neomycin. Relationship between patch test reactions and “use” tests. Arch Dermatol 1979;115:713-5.
5. Uter W, Ramsch C, Aberer W, et al. The European baseline series in 10 European countries, 2005/2006—results of the European Surveillance System on Contact Allergies (ESSCA). Contact Dermatitis 2009;61:31-8.
6. Menezes de Padua CA, Schnuch A, Lessman H, et al. Contact allergy to neomycin sulfate: results of a multifactorial analysis. Pharmacoepidemiol Drug Saf 2005;14:725-33.
7. Zug KA, Warshaw EM, Fowler JF Jr, et al. Patch-test results of the North American Contact Dermatitis Group, 2005-2006. Dermatitis 2009;20:149-60.
8. Rietschel RL, Fowler JF Jr. Topical antimicrobials. In: Rietschel RL, Fowler JF Jr, editors. Fisher's contact dermatitis. 6th ed. Hamilton (ON): BC Decker; 2008. p. 210-29.
9. Andersen KE, White IR, Goossens A. Allergens from the standard series. In: Frosch PJ, Menné T, Lepoittevin JP, editors. Contact dermatitis. 4th ed. Berlin: Springer; 2006. p. 453-92.
10. Phillips DK. Neomycin sulfate. In: Guin JD, editor. Practical contact dermatitis. New York: McGraw-Hill Inc.; 1995. p. 167-77.
11. Epstein E. Contact dermatitis to neomycin with false negative patch tests: allergy established by intradermal and usage tests. Contact Dermatitis 1980;6:236-7.
12. Bjarnason B, Flosadóttir E. Patch testing with neomycin sulfate. Contact Dermatitis 2000;43:295-302.
13. Kimura M, Kawada A. Contact sensitivity induced by neomycin with cross-sensitivity to other aminoglycoside antibiotics. Contact Dermatitis 1998;39:148-50.
14. Schorr WF, Ridgway HB. Tobramycin-neomycin cross-sensitivity. Contact Dermatitis 1977;3:133-7.
15. Forstrom L, Pirila V. Cross-sensitivity within the neomycin group of antibiotics. Contact Dermatitis 1978;4:312.
16. Samsoen M, Metz R, Melchior E, Foussereau J. Cross-sensitivity between aminoside antibiotics. Contact Dermatitis 1980;6:141.
17. Carruthers JA, Cronin E. Incidence of neomycin and framycetin sensitivity. Contact Dermatitis 1976;2:269-70.
18. Rudzki E, Zakrzewski Z, Rebandel P, et al. Cross reactions between aminoglycoside antibiotics. Contact Dermatitis 1988;18:314-6.
19. Sood A, Taylor JS. Bacitracin: allergen of the year. Am J Contact Dermat 2003;14:3-4.
20. Grandinetti PJ, Fowler JF. Simultaneous contact allergy to neomycin, bacitracin and polymyxin. J Am Acad Dermatol 1990; 23:646-7.
21. Van Ketel WG. Polymixine 8-sulfate and bacitracin. Contact Dermatitis Newsl 1974;15:445.
22. Ekelund AG, Móller H. Oral provocation in eczematous contact allergy to neomycin and hydroxyquinolines. Acta Derm Venereol (Stockh) 1969;49:422-6.
23. Menne T, Weismann K. Hamatogenes Kontaktekzem nach oraler Gabe von Neomyzin. Hautartzt 1984;35:319-20.
24. Bouffioux B, Heid E. Eczéma endogène à la néomycine. Nouv Dermatol 1990;9:25.
25. Morton CA, Evans CD, Douglas WS. Allergic contact dermatitis following subconjunctival injection of framycetin. Contact Dermatitis 1993;29:42-3.
26. Jacob SE, Barland C, ElSaie ML. Patch-test-induced “flare-up” reactions to neomycin at prior biopsy sites. Dermatitis 2008;19: E46-8.
27. Guin JD, Phillips D. Erythroderma from systemic contact dermatitis: a complication of systemic gentamicin in a patient with contact allergy to neomycin. Cutis 1989;43:564-7.
28. Haeberle M, Wittner B. Is gentamicin-loaded bone cement a risk for developing systemic allergic dermatitis? Contact Dermatitis 2009;60: 176-7.
29. Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy. Am J Dis Child 1993;147:128-9.
30. Rietschel RL. Neomycin sensitivity and the MMR vaccine. JAMA 1981;245:571.